Liver Molecular-biochemical Markers in Viral Hepatitis B patients

  • Lana Basil Khudhur Department of Biology, Faculty of Science and Health, Koya University, University Park, Kurdistan Region of Iraq.
  • Fakhir Najim Department of Biology, Faculty of Science and Health, Koya University, University Park, Kurdistan Region of Iraq.
Keywords: HBV, qPCR, Liver test.

Abstract

The prevalence of liver disease has led to its emergence as a major challenge. This challenge is also attributed to factors such as the challenging diagnosis, complexity of pathogenesis, and the absence of established therapies. When Hepatitis B virus (HBV) infections occurs in patients that do not have detectable hepatitis B surface antigen (HBsAg), it is referred to as occult infections. Despite the fact that these kinds of infections have been found in patients with chronic hepatitis C liver disease, there is still no evidence on their clinical implication and prevalence. HBV is a small partial deoxy ribonucleic acid (DNA) virus with like retroviruses. The virus falls under the group of Hepadnavirus infections and family of orthohepadna virus. About 66% of patients with acute HBV infection have an asymptomatic, mild, and sub-clinical illness that typically goes undetected. Thus, in this work, hematological parameters were used in detecting the virus, and the results of the hematological parameters revealed significant changes in white blood cell (WBC), lymphocyte and platelet area under curve (AUC) (0.95), (0.66), and (0.82).

The mean values for ALT and ALP in HBV-positive patients increased significantly as compared to the control. Similarly, there was no significant difference between the AUC, CI for HBV-positivity for ALT 0.91, (0.8485-0.9854) and ALP 0.89 (0.8123-0.9633). This study revealed a significant positive correlation between ALP level and ALT and each lymphocyte, granulocyte and WBCs. Thus, each of them may be considered as major factors of development of HBV level.

Downloads

Download data is not yet available.

References

Swietek K, Juszczyk J: Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepat 1997, 4:139-141.
Chrobot AM, Szaflarska-Szczepanik A, Drewa G: Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit 2000, 6:713-718.
Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS: Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Hepatogastroenterology 2003, 50:766-770.
Tanyalcin T, Taskiran D, Topalak O, Batur Y, Kutay F: The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. Hepatol Res 2000, 18:104-109.
Irshad M, Chaudhuri PS, Joshi YK: Superoxide dismutase and total anti-oxidant levels in various forms of liver diseases. Hepatol Res 2002, 23:178-184.
Dandri, M., & Locarnini, S. New insight in the pathobiology of hepatitis B virus infection. Gut, 61 Suppl. 2012;1, i6–i17. https://doi.org/10.1136/gutjnl-2012-302056.
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015 May; 479-480:672-86. doi: 10.1016/j.virol.2015.02.031.
Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23-61. doi: 10.1146/annurev.pathol.1.110304.100230.
Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):36-40. doi: 10.7150/ijms.2.36.
Sorrell, M. F., Belongia, E. A., Costa, J., Gareen, I. F., Grem, J. L., Inadomi, J. M., & Strader, D. B. .National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology, 2009;49,S5:S4-S12.
Ganem D, Schneider RJ. Hepadnaviridae and their replication. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, editors. 2001. Fields Virology. 4. Philadelphia, PA: Lippincott-Raven Publishers.
Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM. Management of chronic hepatitis B. Evidence Report/Technology Assessment No. 174. AHRQ Publication No. 09-E002. Rockville, MD: Agency for Healthcare Research and Quality. 2018.
Quero L, Hanser E, Manigold T, Tiaden AN, Kyburz D. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype. Arthritis Res Ther. 2017 Nov 2;19(1):245. doi: 10.1186/s13075-017-1447-1.
Kondo Y, Ueno Y, Shimosegawa T. Toll-like receptors signaling contributes to immunopathogenesis of HBV infection. Gastroenterol Res Pract. 2011;2011:810939. doi: 10.1155/2011/810939.
Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577-594.e1.
Zhang Q, Wang Y, Zhai N, Song H, Li H, Yang Y, Li T, Guo X, Chi B, Niu J, Crispe IN, Su L, Tu Z. HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway. Sci Rep. 2016;6:36160.
Cao D, Xu H, Guo G, Ruan Z, Fei L, Xie Z, Wu Y, Chen Y. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation. 2013;36:110-120
Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol. 2009;31:345-358.
Elwan N, Salem ML, Kobtan A, El-Kalla F, Mansour L, Yousef M, Al-Sabbagh A, Zidan AA, Abd-Elsalam S. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol Invest. 2018;47:169-180.
Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73:2435-2444.
Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191:1486-1495.
Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res. 2016;76:5696-5706.
Volpi-Lagreca, G., & Duckett, S. K. Supplementation of glycerol or fructose via drinking water to grazing lambs on tissue glycogen level and lipogenesis. Journal of animal science; 2017, 95(6):2558-2575.
Iwakiri, Y., Grisham, M., & Shah, V. Vascular biology and pathobiology of the liver: Report of a single‐topic symposium. Hepatology; 2008, 47 (5):1754-1763.
Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology; 2000, 31: 1037– 1044.
Lammert, F., Gurusamy, K., Ko, C. W., Miquel, J. F., Méndez-Sánchez, N., Portincasa, P., & Wang, D. Q. H. Gallstones. Nature reviews Disease primers; 2016, 2 (1): 1-17.
Tsai, T.Y., Peng, C.Y., Yang, H.I., Huang, Y.L., Tao, M.H., Yuan, S.S., Lai, H.C. and Hsieh, S.L., 2018. The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection. Journal of biomedical science, 25(1):.59.
Seeger C, Mason WS. Hepatitis B virus biology. Microbiology & Molecular Biology Reviews; 2000, 64:51–68.
Liaw, Y. F., & Chu, C. M. Hepatitis B virus infection. The lancet; 2009, 373 (9663): 582-592.
Ghany, M., & Liang, T. J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology; 2007, 132 (4): 1574-1585.
Hou, J., Liu, Z., & Gu, F. Epidemiology and prevention of hepatitis B virus infection. International journal of medical sciences; 2005, 2 (1): 50.
Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology; 2003, 24: 327– 334.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC gastroenterology; 2006, 6(1): 6-13.
Hwang EW, Cheung R. Global epidemiology of hepatitis B virus (HBV) infection. North American Journal of Medicine and Science; 2011, 4 (1): 92-115.
Jaroszewicz J, Serrano BC, Wursthorn K, Deterding K, Schlue J, Raupach R. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. Journal of hepatology; 2010, 52 (4): pp. 514–522.
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC gastroenterology; 2006, 6(1): 34.
Bottero J, Lacombe K, Guéchot J, Serfaty L, Miailhes P, Bonnard P. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. Journal of hepatology; 2009, 50 (6):1074–1083.
Beaugrand M. Non-Invasive Liver Assessment. Textbook of Clinical Gastroenterology and Hepatology. Wiley-Blackwell. 2012.
Published
2021-06-20
How to Cite
Basil Khudhur, L. and Najim, F. (2021) “Liver Molecular-biochemical Markers in Viral Hepatitis B patients”, Zanco Journal of Pure and Applied Sciences, 33(3), pp. 85-97. doi: 10.21271/ZJPAS.33.3.9.
Section
Biology and Medical Researches